Clinical trials
Heart Failure With Normal Ejection Fraction clinical trials
Below are recruiting heart failure with normal ejection fraction clinical trials, each written for real people, not researchers. We’re tracking 63 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06570473RecruitingPhase 2
RV failure treatment trial for pulmonary hypertension patients
This trial is testing two heart medications, empagliflozin and ranolazine, to see if they can improve right heart function in people with pulmonary hypertension and right ventricular failure. Participants will monitor their symptoms using a smartphone or tablet.
Calgary, AlbertaAges 18 years+ - NCT06907017Recruiting
CorWave left heart pump first-in-human study
This trial tests a new left ventricular assist device (LVAD) for people with advanced heart failure who are not responding to standard treatments and are eligible for a heart transplant. The pump helps the heart circulate blood.
Sydney, New South WalesAges 18–75 - NCT07207811RecruitingPhase 3
Study of coramitug for heart failure from ATTR amyloidosis
This study tests an investigational medicine called coramitug in people with heart failure caused by ATTR amyloidosis, a condition where abnormal protein builds up in the heart. The goal is to see if it can slow or improve heart function.
Phoenix, ArizonaAges 18 years+ - NCT06902896RecruitingPhase 1/Phase 2
FAP iCDC therapy for advanced heart failure from dilated cardiomyopathy
This trial tests a new treatment called FAP iCDC for people with end-stage dilated cardiomyopathy, a type of heart muscle disease. It aims to see if this therapy is safe and helps improve heart function when standard medicines are no longer enough.
Hangzhou, ZhejiangAges 18–75 - NCT04162444Recruiting
Aortic valve reconstruction study for children
This trial studies a surgery approach to help fix a narrowed or leaking aortic valve in children. It aims to see how well the reconstructed valve works and how it affects the child’s heart function over time.
MoscowAges 4 weeks–12 years - NCT04591639Recruiting
DAPA test for diabetes and heart failure using body scans
This study tests how a medication called DAPA (an SGLT2 inhibitor) affects the body in people with heart failure (with or without type 2 diabetes), or in some people with type 2 diabetes only. It may help researchers understand who could benefit most and what changes happen in the heart, using specialized heart imaging.
Edinburgh, ScotlandAges 18 years+ - NCT05712824Recruiting
Device to measure left-heart pressure in advanced heart failure
This trial tests a wirelessly implanted device that measures pressure in the left upper heart chamber (left atrial pressure) in people with advanced heart failure. By tracking that pressure, researchers hope to better understand disease status and guide care.
Tbilisi, GeorgiaAges 22–88 - NCT05793996RecruitingPhase 4
Testing an iron infusion for iron deficiency in HFpEF
This study checks how common iron deficiency is in people with HFpEF (heart failure with preserved pumping strength) and tests whether an iron infusion (Ferinject®) improves health. It targets people with stable heart symptoms and lab results showing low iron stores or related iron deficiency.
TomskAges 18 years+ - NCT06147336Recruiting
Testing the V-Lap system for heart failure monitoring
This trial tests a new device called V-Lap that is placed in the heart to monitor pressure. It may help doctors better manage heart failure and reduce hospital stays. Researchers want to see if it works well in people with mild to moderate heart failure.
Boston, MassachusettsAges 22–88 - NCT07516288RecruitingPhase 1
Second CAR-DC Cell Infusion for Advanced Heart Failure
This trial tests a second dose of specialized immune cells (called CAR-DC) in patients with severe dilated cardiomyopathy (a weakened heart muscle) who received one dose before but saw their heart function decline back to baseline. The goal is to see if a second dose is safe and can improve heart function when the first treatment's benefits wore off.
Hangzhou, Zhejiang / 浙江Ages 18–75 - NCT07427199Recruiting
Digital nutrition therapy after heart attack
This study tests whether a digital nutrition program (app- or online-based) can improve heart function after a heart attack. It compares the program to standard care for people who have had a STEMI heart attack.
Samsun, AtakumAges 19–65 - NCT05672836RecruitingPhase 4
Enavogliflozin after TAVR for heart narrowing with mild heart weakness
This trial tests enavogliflozin (a diabetes medication that may help the heart) in people who have had a TAVR procedure for severe aortic stenosis. It looks at whether the medicine can improve outcomes for people with symptoms and mildly reduced or preserved pumping function.
Bucheon-siAges 19 years+ - NCT07489547RecruitingPhase 2/Phase 3
Can stable heart failure patients stop some medications?
This trial is testing whether people whose heart failure has improved (with better pumping strength) can safely stop taking some of their heart medications. It is for stable patients who have had significant improvement in their heart function from a low point.
Porto Alegre, Rio Grande do SulAges 18 years+ - NCT05628779Enrolling by invitation
Clip procedure to repair a leaking tricuspid valve
This trial studies a minimally invasive “edge-to-edge” clip procedure to reduce severe leakage of the tricuspid valve. It’s for people who still feel unwell despite standard treatments and may be too high-risk for open-heart surgery.
AmsterdamAges 18 years+ - NCT01174108RecruitingPhase 2
Stem cell transplant with donor T-cells for severe bone marrow failure
This Phase 2 study tests a specific type of donor stem cell transplant for severe bone marrow failure conditions, aiming to improve cure rates while reducing transplant risks. It includes people with diseases like severe aplastic anemia and certain bone marrow disorders, especially when standard transplant plans feel too risky.
Baltimore, MarylandAges 4–80
Hear when a new Heart Failure With Normal Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for heart failure with normal ejection fraction?
- Yes. Clin2 currently lists 63 recruiting heart failure with normal ejection fraction studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a heart failure with normal ejection fraction trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a heart failure with normal ejection fraction trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Heart Failure With Preserved Ejection Fraction
- Heart Failure With Reduced Ejection Fraction
- Heart Failure With Mildly Reduced Ejection Fraction
- Heart Failure With Mid Range Ejection Fraction
- Chronic Heart Failure With Reduced Ejection Fraction
- Acute Heart Failure
- Chronic Heart Failure
- Congestive Heart Failure
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.